REVB REVELATION BIOSCIENCES, INC.

Nasdaq revbiosciences.com


$ 1.35 $ 0.00 (0 %)    

Tuesday, 14-Oct-2025 10:54:35 EDT
QQQ $ 597.23 $ 2.15 (0.36 %)
DIA $ 460.29 $ 3.28 (0.72 %)
SPY $ 660.26 $ 2.95 (0.45 %)
TLT $ 90.56 $ -0.08 (-0.09 %)
GLD $ 380.30 $ 2.00 (0.53 %)
$ 1.34
$ 1.34
$ 1.35 x 442
$ 1.36 x 200
-- - --
$ 1.28 - $ 60.48
293,812
na
2.28M
$ 0.23
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-22-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-22-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-14-2022 03-31-2022 10-Q
15 04-15-2022 12-31-2021 10-K
16 10-29-2021 09-30-2021 10-Q
17 08-23-2021 06-30-2021 10-Q
18 06-22-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 11-16-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 revelation-biosciences-announces-immediate-exercise-of-436m-warrants-at-220share

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences comp...

 revelation-biosciences-reports-gemini-significantly-reduced-inflammatory-activity-and-restored-normal-cellular-response-in-stage-3-and-4-ckd-patients

Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients.Gemini could potentially revolu...

 watching-revelation-bios-zacks-small-cap-research-gives-stock-2145-price-valuation

https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_08082025_REVB_Sorensen.pdf

 revelation-biosciences-q2-eps-701-misses-149-estimate

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(7.01) per share which missed the analyst consensus estimate...

 cder-director-tidmarsh-will-be-acting-head-of-fda-biologics-center-following-prasad-exit--endpoints-news

https://endpoints.news/cder-director-tidmarsh-will-be-acting-head-of-fda-biologics-center-following-prasad-exit/

 watching-revelation-biosciences-zacks-small-cap-research-gives-stock-2145share-valuation

https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_07092025_REVB_Sorensen.pdf

 us-stocks-likely-to-open-higher-sp-500-sees-average-gain-of-61-in-2nd-half-expert-says

U.S. futures rose on Wednesday after a mixed close on Tuesday. Futures of major benchmark indices were trading slightly higher.

 revelation-biosciences-announces-pricing-of-4m-public-offering-of-up-to-1456m-shares-at-an-offering-price-of-110shr

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences comp...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION